Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.

Intrinsic and acquired resistance to current HER2 targeted therapies remains a challenge in clinics. We have developed a therapeutic HER2 siRNA delivered using mesoporous silica nanoparticles modified with polymers and conjugated with HER2 targeting antibodies. Our previous studies have shown that o...

Full description

Saved in:
Bibliographic Details
Main Authors: Shenda Gu, Worapol Ngamcherdtrakul, Moataz Reda, Zhi Hu, Joe W Gray, Wassana Yantasee
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0198141/1/pone.0198141.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210223%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210223T093907Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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
Tags: Add Tag
No Tags, Be the first to tag this record!